Skip to content

Unicycive Therapeutics Inc Sustainability Reports

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for kidney diseases. Its lead product candidates include oxylanthanum carbonate for hyperphosphatemia and UNI-494 for acute kidney injury.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

3 reports from 2022 to 2024